Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
376
datasets available to search
ShareScore release 0.9.0
Dataset results
376 results for “patient benefits”
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
ClinicalTrials.gov study NCT00796445. IPD Sharing: YES. Countries: 32. Publications: 2.
A Study for the Assessment of the Benefits of a Novel Mesh Nebulizer in the Treatment of Patients With Stable COPD
ClinicalTrials.gov study NCT03933462. IPD Sharing: NO. Countries: 1. Publications: 1.
How OMT Benefits Newly Diagnosed Patients With Respiratory Illness When Given Alongside Other Standard Care.
ClinicalTrials.gov study NCT06495021. IPD Sharing: NO. Countries: 1. Publications: 9.
Clinical Categorization Algorithm (Clical) and Machine-Learning Approach (Srf-clical) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-world Evidence from Istituto Nazionale Tumori Irccs Fondazione Pascale, Napoli, Italy.
<p>Raw-data related to a manuscript submitted to "Cancers" journal - MDPI - https://www.mdpi.com/journal/cancers</p> <p><strong>Manuscript Title</strong>: Clinical Categorization Algorithm (Clical) and Machine-Learning Approach (Srf-clical) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-world Evidence from Istituto Nazionale Tumori Irccs Fondazione Pascale, Napoli, Italy.</p> <p><strong>Authors:</strong> Gabriele Madonna1,#, Giuseppe V. Masucci2,3,#, Mariaelena Capone1, Domenico Mallardo1, Antonio Maria Grimaldi1, Ester Simeone1, Vito Vanella1, Lucia Festino1, Marco Palla1, Luigi Scarpato1, Marilena Tuffanelli1, Grazia D’angelo1, Lisa Villabona2, Isabelle Krakowski2,4, Hanna Eriksson2,3, Felipe Simao5, Rolf Lewensohn2,3, Paolo Antonio Ascierto1,+</p> <p><strong>Affiliations</strong>:</p> <p>1 Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy</p> <p>2 Theme Cancer, Karolinska University Hospital, Stockholm, Sweden</p> <p>3 Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden</p> <p>4 Theme Inflammation, Karolinska University Hospital Stockholm, Sweden</p> <p>5 Genevia technologies OY, Tampere, Finland</p> <p># these authors equally contributed</p> <p>+ Corresponding author</p> <p><strong>Abstract of submitted Manuscript:</strong> The real-life application of immune checkpoint inhibitors (ICI) may yield different outcomes compared to the benefit presented in clinical trials. For this reason, there is a need to define the group of patients that may benefit from treatment. We retrospectively investigated 578 metastatic melanoma patients treated with ICI at Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale” of Napoli Italy (INT-NA). To compare patients’ clinical variables (age, Lactate Dehydrogenase (LDH), Neutrophil-Lymphocyte Ratio (NLR), eosinophil, BRAF status, previous treatment) and their predictive and prognostic power in a comprehensive non-hierarchical way, a Clinical Categorization Algorithm (CLICAL) was defined and validated by the application of machine learning, Survival Random Forest (SRF-CLICAL). The comprehensive analysis of the clinical parameters by log risk-based algorithms convened into predictive signatures that could identify groups of patients with great benefit or not, regardless of the ICI received. From a real-life retrospective analysis of metastatic melanoma patients, we generated and validated an algorithm based on machine learning that could assist with the clinical decision of whether or not to apply ICI therapy by defining five signatures of predictability with a 95% accuracy.</p> <p><strong>Funding: </strong>This research was funded by Italian Ministry of Health (IT-MOH) through “Ricerca Corrente”, grants number M2-2. Additional funding [N#184093) from the Stockholm Cancer Society and King Gustav V’s Jubilee foundation Stockholm.</p>
Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade
<p>Different biomarkers based on genomics variants have been used to predict the response of patients treated with PD-1/programmed death receptor 1 ligand (PD-L1) blockade. We aimed to use deep-learning algorithm to estimate clinical benefit in patients with non-small-cell lung cancer (NSCLC) before immunotherapy. Peripheral blood samples or tumor tissues of 915 patients from three independent centers were profiled by whole-exome sequencing or next-generation sequencing. Based on convolutional neural network (CNN) and three conventional machine learning (cML) methods, we used multi-panels to train the models for predicting the durable clinical benefit (DCB) and combined them to develop a nomogram model for predicting prognosis. In the three cohorts, the CNN achieved the highest area under the curve of predicting DCB among cML, PD-L1 expression, and tumor mutational burden (area under the curve [AUC] = 0.965, 95% confidence interval [CI]: 0.949–0.978, <em>P</em> < 0.001; AUC =0.965, 95% CI: 0.940–0.989, <em>P</em> < 0.001; AUC = 0.959, 95% CI: 0.942–0.976, <em>P</em> < 0.001, respectively). Patients with CNN-high had longer progression-free survival (PFS) and overall survival (OS) than patients with CNN-low in the three cohorts. Subgroup analysis confirmed the efficient predictive ability of CNN. Combining three cML methods (CNN, SVM, and RF) yielded a robust comprehensive nomogram for predicting PFS and OS in the three cohorts (each <em>P</em> < 0.001). The proposed deep-learning method based on mutational genes revealed the potential value of clinical benefit prediction in patients with NSCLC and provides novel insights for combined machine learning in PD-1/PD-L1 blockade.</p>
Music Use and Perceived Psycho-social Benefits of Music of Caregivers of Patients in an Intensive Care Unit
ClinicalTrials.gov study NCT03156192. IPD Sharing: NO. Countries: 1. Publications: 4.
The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient
ClinicalTrials.gov study NCT04689971. IPD Sharing: NO. Countries: 1. Publications: 10.
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
ClinicalTrials.gov study NCT03757013. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Benefits of Post-Pyloric Feeding Tubes in Critically Ill Patients
ClinicalTrials.gov study NCT01343316. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Understanding the Benefits of Dietary Fibre Supplementation in Patients With Prostate Cancer
ClinicalTrials.gov study NCT06661044. IPD Sharing: NO. Countries: 1. Publications: 16.
Holistic Nursing Benefits Cognitive and Psychiatric Symptoms in Alzheimer's Patients
ClinicalTrials.gov study NCT06868004. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Benefit of Cheyne-Stokes Respiration Remote Monitoring in CPAP-treated Patients With Obstructive Sleep Apnea to Detect Early Events of Heart Failure.
ClinicalTrials.gov study NCT03592108. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Major Surgical Procedures.
ClinicalTrials.gov study NCT02138591. IPD Sharing: Not stated. Countries: 1. Publications: 12.
The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / FTC / TAF Treatment in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infect
ClinicalTrials.gov study NCT05606055. IPD Sharing: NO. Countries: 1. Publications: 2.
The Benefit of Arthroscopic Partial Meniscectomy in Middle-Aged Patients
ClinicalTrials.gov study NCT01264991. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation
ClinicalTrials.gov study NCT01204307. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
ClinicalTrials.gov study NCT02066519. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Long-Term Benefits of Eccentric Cycling Exercise in Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT07109102. IPD Sharing: NO. Countries: 1. Publications: 12.
Study Examines the Feasibility, Safety and Benefits of Using a Specific Suspension Walking Device for Patients With Neurological Damage
ClinicalTrials.gov study NCT04300491. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Patient Perceptions and Physician Assessment of Benefits and Risks of Oral Anticoagulation Due to Non-valvular AF
ClinicalTrials.gov study NCT03061123. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.